Today's Rundown Gilead's remdesivir speeds COVID-19 recovery in first controlled trial readout, but it's no 'silver bullet' 'Operation Warp Speed' aims to deliver a COVID-19 vaccine by year's end: Bloomberg Apple, Google and Amazon are sprinting to battle COVID-19. Here are lessons that can be learned J&J inks 2nd manufacturing deal to boost capacity for COVID-19 vaccine Pfizer, BioNTech finish dosing in COVID-19 vax test; emergency use could start in the fall Quest, LabCorp launch nationwide COVID-19 antibody testing in pharmacies and online More PPE? Better telemedicine coverage? New group aims to organize physicians around top concerns Humana pulls outlooks for Medicaid, small and large group plan memberships due to COVID-19 Hospitals needed to rapidly find more beds due to COVID-19. Tufts Medical Center looked to patients' homes AstraZeneca, with a heavy focus on China, sees key meds outperform despite COVID-19 Though sales are up, Boston Scientific's net Q1 profit shrinks to $11M in the face of COVID-19 House lawmakers want new flexibility to ensure hospitals don't lose 340B eligibility due to COVID-19 response GlaxoSmithKline fields worries about fast-growing Shingrix as COVID-19 halts routine doc visits Featured Story | | | Wednesday, April 29, 2020 After dribs and drabs surfacing about Gilead’s COVID-19 hopeful, remdesivir, the first data from a placebo-controlled study are here—at least, an early look at them. Remdesivir cut recovery time for hospitalized COVID-19 patients by four days, or 31%, in an NIH-sponsored study pitting the drug against placebo in more than 1,000 patients. |
|
|---|
|
Top Stories Wednesday, April 29, 2020 Biopharma players worldwide have committed big money and talent to the hunt for a COVID-19 vaccine, and experts predict a shot might be available in 12 to 18 months. Behind the scenes, the Trump administration is working up a Manhattan Project-type initiative to further accelerate the work, Bloomberg reports. Wednesday, April 29, 2020 U.S. tech giants have quickly brought their innovations to the front lines amid COVID-19. Find out how Amazon, Apple and Google are racing to use their technologies and services to battle the novel coronavirus. Wednesday, April 29, 2020 Johnson & Johnson, one of a wave of companies racing to produce a vaccine for the novel coronavirus, aims to sign up a network of manufacturing partners to help boost capacity ahead of a potential FDA approval. Now, in its second sweeping production deal, J&J has paired up with Catalent to set the stage for the shot's debut. Wednesday, April 29, 2020 Pfizer and partner BioNTech are keeping pace with the speed of the sweeping pandemic as they finish dosing in the first cohort of their COVID-19 inoculation test. Wednesday, April 29, 2020 Weeks after launching their own COVID-19 molecular testing initiatives, lab giants Quest Diagnostics and LabCorp have begun offering antibody tests nationwide for the next phase of the coronavirus pandemic. Tuesday, April 28, 2020 With mounting concerns about safety and the financial security of physicians during COVID-19, organizers say the new group called United Physicians will take advantage of virtual platforms to pull together a large number around the issues they most care about. Wednesday, April 29, 2020 The COVID-19 pandemic didn't have a major impact on the insurer's first-quarter earnings, but that could change in the months ahead. Wednesday, April 29, 2020 Much of the rush to create capacity among the surges of novel coronavirus cases centered on reworking hospital units or quickly building out field hospitals. Tufts Medical Center in Boston is looking to a different answer: offering hospital-level acute care in patients' homes. Wednesday, April 29, 2020 When the novel coronavirus put China on high alert, there were concerns that the outbreak would hit AstraZeneca hard, given its high exposure to the country. But the company managed to grow sales ahead of expectations, thanks to its oncology portfolio and respiratory med Symbicort. Wednesday, April 29, 2020 Though its first-quarter sales were up—due in no small part to the closure of its $4.2 billion acquisition of BTG last year—Boston Scientific’s total net income shrank down to a slim margin compared to 2019’s lead-off quarter. Wednesday, April 29, 2020 House lawmakers are pressing leadership to include in the next financial relief package new flexibility for hospitals to keep their 340B eligibility. Wednesday, April 29, 2020 Wellness visits, including vaccinations, have plummeted in the time of COVID-19, GlaxoSmithKline acknowledged Wednesday. But how much will that affect its high-flying shingles vaccine Shingrix? Executives downplayed the impact and laid out a plan for restarting demand for the shot, its fastest-growing product, later this year. |
